Additional file 2 of Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial (original) (raw)

Additional file 2 of Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

2021

Abstract

Additional file 2: Table S1. Hypersensitivity TEAEs (PT) on or after the date of subject first ADA-positive test (safety population; TP3).

Daniel Alvarez hasn't uploaded this paper.

Let Daniel know you want this paper to be uploaded.

Ask for this paper to be uploaded.